Table of Content
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Technology
1.1.2. Application
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.3.5.1. Data for primary interviews in North America
1.3.5.2. Data for primary interviews in Europe
1.3.5.3. Data for primary interviews in Asia Pacific
1.3.5.4. Data for primary interviews in Latin America
1.3.5.5. Data for Primary interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology Outlook
2.2.2. Application Outlook
2.2.3. Regional Outlook
2.3. Competitive Insights
Chapter 3. Transdermal Drug Delivery System Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing Adoption of Transdermal Patches
3.4.1.2. Technological Advancements
3.4.1.3. High Demand for Pain Free Drug Delivery
3.4.2. Market restraint analysis
3.4.2.1. High Cost of Transdermal Technology
3.4.2.2. Limited Number of Approved Medications
3.5. Transdermal Drug Delivery System Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Transdermal Drug Delivery System Device: Technology Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Electroporation
4.1.2. Radio Frequency
4.1.3. Iontophoresis
4.1.4. Microporation
4.1.5. Thermal
4.1.6. Mechanical arrays
4.1.7. Ultrasound
4.1.8. Others
4.2. Technology Market Share, 2022& 2030
4.3. Segment Dashboard
4.4. Global Transdermal Drug Delivery System Market by Technology Outlook
4.5. Market Application& Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5.1. Electroporation
4.5.1.1. Market estimates and forecast 2018 – 2030 (Revenue in USD Million)
4.5.2. Radio Frequency
4.5.2.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
4.5.3. Iontophoresis
4.5.3.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
4.5.4. Microporation
4.5.4.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
4.5.5. Thermal
4.5.5.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
4.5.6. Mechanical Arrays
4.5.6.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
4.5.7. Ultrasound
4.5.7.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
4.5.8. Others
4.5.8.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
Chapter 5. Transdermal Drug Delivery System: Application Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. CNS
5.1.2. Pain Management
5.1.3. Cardiovascular
5.1.4. Hormone
5.1.5. Immunological
5.1.6. Metabolic
5.1.7. Gastrointestinal
5.1.8. Infection
5.1.9. Cancer
5.1.10. Others
5.2. Application Market Share, 2022& 2030
5.3. Segment Dashboard
5.4. Global Transdermal Drug Delivery System Market by Application Outlook
5.5. Market Application& Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5.1. CNS
5.5.1.1. Market estimates and forecast, 2018 – 2030(Revenue in USD Million)
5.5.2. Pain Management
5.5.2.1. Market estimates and forecast, 2018 – 2030(Revenue in USD Million)
5.5.3. Cardiovascular
5.5.3.1. Market estimates and forecast, 2018 – 2030(Revenue in USD Million)
5.5.4. Hormone
5.5.4.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.5. Immunological
5.5.5.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.6. Metabolic
5.5.6.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.7. Gastrointestinal
5.5.7.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.8. Infection
5.5.8.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.9. Cancer
5.5.9.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.10. Others
5.5.10.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.10.2. Urological
5.5.10.2.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.10.3. Blood Disorders
5.5.10.3.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.10.4. Respiratory
5.5.10.4.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
5.5.10.5. Musculoskeletal
5.5.10.5.1. Market estimates and forecast, 2018 – 2030 (Revenue in USD Million)
Chapter 6. Market: Regional Estimates & Trend Analysis
6.1. Regional market share analysis, 2022& 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. Regional Market Share and Leading Players, 2022
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. Latin America
6.4.5. Middle East and Africa
6.5. SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.5.1. North America
6.5.2. Europe
6.5.3. Asia Pacific
6.5.4. Latin America
6.5.5. Middle East and Africa
6.6. Market Application, & Forecasts and Trend Analysis, 2018 to 2030:
6.7. North America
6.7.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.2. U.S.
6.7.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.7.3. Canada
6.7.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8. Europe
6.8.1. U.K.
6.8.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8.2. Germany
6.8.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8.3. France
6.8.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8.4. Italy
6.8.4.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8.5. Spain
6.8.5.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8.6. Denmark
6.8.6.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8.7. Sweden
6.8.7.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.8.8. Norway
6.8.8.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.9. Asia Pacific
6.9.1. Japan
6.9.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.9.2. India
6.9.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.9.3. China
6.9.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.9.4. South Korea
6.9.4.1 Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.9.5. Thailand
6.9.5.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.9.6. Australia
6.9.6.1 Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.10. Latin America
6.10.1. Brazil
6.10.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.10.2. Mexico
6.10.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.10.3. Argentina
6.10.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.11. MEA
6.11.1. South Africa
6.11.1.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.11.2. Saudi Arabia
6.11.2.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.11.3. UAE
6.11.3.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
6.11.4. Kuwait
6.11.4.1. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Innovators
7.2.2. Market Leaders
7.2.3. Emerging Players
7.3. Vendor Landscape
7.3.1. List of key distributors and channel partners
7.3.2. Key customers
7.3.3. Key company market share analysis, 2022
7.3.4. Novartis AG
7.3.4.1. Company overview
7.3.4.2. Financial performance
7.3.4.3. Product benchmarking
7.3.4.4. Strategic initiatives
7.3.5. Johnson & Johnson
7.3.5.1. Company overview
7.3.5.2. Financial performance
7.3.5.3. Product benchmarking
7.3.5.4. Strategic initiatives
7.3.6. Mylan Pharmaceuticals, Inc.
7.3.6.1. Company overview
7.3.6.2. Financial performance
7.3.6.3. Product benchmarking
7.3.6.4. Strategic initiatives
7.3.7. Boehringer Ingelheim GmbH Overview
7.3.7.1. Financial performance
7.3.7.2. Product benchmarking
7.3.7.3. Strategic initiatives
7.3.8. Biogel Technology, Inc.
7.3.8.1. Company overview
7.3.8.2. Financial performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Transdermal Technologies, Inc.
7.3.9.1. Company overview
7.3.9.2. Financial performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Skyepharma
7.3.10.1. Company overview
7.3.10.2. Financial performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Watson Pharmaceuticals, Inc.
7.3.11.1. Company overview
7.3.11.2. Financial performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
7.3.12. 3M Company
7.3.12.1. Company overview
7.3.12.2. Financial performance
7.3.12.3. Product benchmarking
7.3.12.4. Strategic initiatives
7.3.13. Noven Pharmaceuticals, Inc.
7.3.13.1. Company overview
7.3.13.2. Financial performance
7.3.13.3. Product benchmarking
7.3.13.4. Strategic initiatives
7.3.14. 4P Therapeutics, LLC
7.3.14.1. Company overview
7.3.14.2. Financial performance
7.3.14.3. Product benchmarking
7.3.14.4. Strategic initiatives
7.3.15. Transdermal Corporation
7.3.15.1. Company overview
7.3.15.2. Financial performance
7.3.15.3. Product benchmarking
7.3.15.4. Strategic initiatives
7.3.16. Echo Therapeutics, Inc.
7.3.16.1. Company overview
7.3.16.2. Financial performance
7.3.16.3. Product benchmarking
7.3.16.4. Strategic initiatives
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer